A Phase 2 Single-arm Study to Evaluate Safety and Efficacy of CRS-207 With Pembrolizumab in Adults With Previously-Treated Malignant Pleural Mesothelioma
Phase of Trial: Phase II
Latest Information Update: 18 Dec 2017
At a glance
- Drugs CRS 207 (Primary) ; Pembrolizumab
- Indications Mesothelioma
- Focus Therapeutic Use
- Sponsors Aduro BioTech
- 12 Dec 2017 Status changed from active, no longer recruiting to discontinued, according to an Aduro BioTech media release.
- 12 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 28 Jun 2017 According to an Aduro BioTech media release, first patients has been dosed.